Search results
Results from the WOW.Com Content Network
Hormone levels following a single intramuscular injection of EV/NETE (5 mg/50 mg) in healthy young men. [9] Testosterone levels were maximally suppressed by about 94%, to ~30 ng/dL, when measured at day 7. [9] EV/NETE is a combination of EV, an estrogen, and NETE, a progestogen with weak androgenic activity.
In transgender women, estradiol valerate given by intramuscular injection is usually used at a dosage of 5 to 20 mg, but up to 30 to 40 mg, once every 2 weeks. [ 30 ] [ 31 ] [ 29 ] Estradiol valerate has also been used at a dose of 10 to 40 mg by intramuscular injection to limit bleeding in women with hemorrhage due to dysfunctional uterine ...
A 3.75-cm (1.5-inch), 21-gauge needle is generally used, but obese individuals may require a 6.5-cm (2.5-inch) needle to ensure that the drug is indeed injected intramuscularly and not subcutaneously. [6] Haloperidol decanoate is provided in the form of 50 or 100 mg/mL oil solution of sesame oil and benzyl alcohol in ampoules or pre-filled ...
Equianalgesic charts are used for calculation of an equivalent dose (a dose which would offer an equal amount of analgesia) between different analgesics. [1] Tables of this general type are also available for NSAIDs , benzodiazepines , depressants , stimulants , anticholinergics and others.
25–50 mg/day Enzalutamide: Xtandi: Antiandrogen: Oral: 160 mg/day GnRH analogue: Various: GnRH modulator: Various: Variable Elagolix: Orilissa: GnRH antagonist: Oral: 150 mg/day or 200 mg twice daily Finasteride: Propecia: 5αR inhibitor: Oral: 1–5 mg/day Dutasteride: Avodart: 5αR inhibitor: Oral: 0.25–0.5 mg/day Progesterone: Prometrium ...
The full endometrial transformation dosage of EB/P4 in oil solution is 1 to 2 mg EB and 20 to 25 mg P4 by intramuscular injection daily for 10 to 14 days, whereas the full endometrial transformation dosage of EB/P4 in microcrystalline aqueous suspension is a single intramuscular injection of 10 mg EB and 200 mg P4. [6]
Estradiol undecylate has been used as a form of high-dose estrogen therapy to treat prostate cancer, but has since largely been superseded for this indication by newer agents with fewer adverse effects (e.g., gynecomastia and cardiovascular complications) like GnRH analogues and nonsteroidal antiandrogens.
A dosage of nandrolone decanoate of 25 to 50 mg once every 6 to 12 weeks (working out to an average exposure of about 2 to 8 mg per week) by intramuscular injection is considered to be appropriate for general androgen replacement therapy in women.